Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493649 · ClinicalTrials.gov registry record · Phase 2
Adj TC + Herceptin Early Stage Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by US Oncology Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 493
- Enrollment target
- 20
- Study locations
NCT00493649: Completed Phase 2 study of Breast Cancer, sponsored by US Oncology Research.
NCT00493649 is a Phase 2 study of Breast Cancer that has completed, run by US Oncology Research. The registered enrollment target is 493 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00493649, a Phase 2 study of Breast Cancer, has completed, sponsored by US Oncology Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 493 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this research study is to find out what effects (good and bad) docetaxel/cyclophosphamide (brand names: Taxotere and Cytoxan, or TC) plus trastuzumab (brand name: Herceptin, or H) has HER2+ breast cancer.
Primary Outcome
DFS was measured from the date of registration to either the date the patient was first recorded as having disease recurrence, or the date of death due to any causes before recurrence. If a patient had not recurred or died, DFS was censored at the date of last follow-up.
Conditions Studied
Interventions
- DRUG Taxotere
- DRUG Cytoxan
- DRUG Herceptin
Study Locations (20)
Arizona
- Hematology Oncology Associates - Phoenix
- Northern AZ Hematology & Oncology Associates - Sedona
- Arizona Oncology Associates DBA HOPE - Tucson
Florida
- Florida Cancer Institute - New Port Richey
- Ocala Oncology Center - Ocala
- Cancer Centers of Florida, P.A. - Ocoee
Illinois
- Hematology Oncology Associates of IL - Chicago
- Cancer Care & Hematology Specialists of Chicagoland - Niles
Indiana
- Central Indiana Cancer Centers - Indianapolis
- Hope Center - Terre Haute
Maryland
- Maryland Oncology Hematology, P.A. - Columbia
- Alliance Hematology Oncology P.A. - Westminster
Missouri
- Missouri Cancer Associates - Columbia
- Arch Medical Services, Inc. - St Louis
Alabama
- Birmingham Hematology and Oncology - Birmingham
Colorado
- Rocky Mountain Cancer Center-Rose - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 493 participants |
| Start Date | 2007-06 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
What the finished NCT00493649 record still lists
NCT00493649 is an interventional study that assigns participants to a tested intervention. The registered 493 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Taxotere is the first listed.
NCT00493649 names 20 study sites across 12 states, led by Arizona, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00493649 about?
NCT00493649 is a clinical study titled "Adj TC + Herceptin Early Stage Breast Cancer". The purpose of this research study is to find out what effects (good and bad) docetaxel/cyclophosphamide (brand names: Taxotere and Cytoxan, or TC) plus trastuzumab (brand name: Herceptin, or H) has HER2+ breast cancer.
What is the current status of trial NCT00493649?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 493 participants. The study started on 2007-06. Estimated completion is 2013-04.
What conditions does trial NCT00493649 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00493649?
The interventions under investigation include: Taxotere (DRUG), Cytoxan (DRUG), Herceptin (DRUG).
Who is sponsoring clinical trial NCT00493649?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00493649 being conducted?
This trial has 20 study locations across Alabama, Arizona, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00493649's enrollment target sits among peer trials
493 204th of 1224 higher than 1,020 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05861973 · 492 participants · NA
SMARTer Weight Loss Management
- NCT05908331 · 492 participants · NA
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
- NCT06152575 · 492 participants · Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- NCT06953089 · 492 participants · Phase 2
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia